Full-Time

Senior Scientist – NHP Study Lead / Analyst

Stylus Medicine

Stylus Medicine

11-50 employees

In vivo genome editing for CAR-T

Compensation Overview

$160k - $175k/yr

Cambridge, MA, USA

In Person

Limited travel may be required.

Category
Biology & Biotech (1)
Requirements
  • PhD in Pharmacology, Immunology, Immuno-oncology, or a related field with 4-6 years of relevant industry or academic experience, or a Master's degree with 8+ years of experience
  • Demonstrated experience with ex vivo analytical techniques, such as flow cytometry, cytokine analysis, and digital droplet PCR
  • Demonstrated ability to design, execute, interpret, and troubleshoot immunology-related in vivo studies and to coordinate the activities of multiple study contributors
  • Experience coordinating with animal vendors, CROs or external collaborators
  • Experience with T cell or peripheral blood mononuclear cell isolation and handling and related downstream immunological or molecular assays
Responsibilities
  • Design nonhuman primate study protocols and lead contract research organization communication
  • Analyze, interpret, and communicate nonhuman primate study data, including flow cytometry analysis, cytokine analysis and other ex vivo readouts, to inform project direction and decision-making
  • Evaluate data for consistency and follow-up as needed, working closely with contract research organizations to optimize study protocols
  • Investigate and interpret biological findings from nonhuman primate studies
  • Manage nonhuman primate study test article generation and transfer in collaboration with internal cross-functional teams
  • Conduct experiments to optimize protocols for contract research organization transfer or investigate biological findings
  • Generate and manage study documentation, including protocols and study reports
  • Effectively communicate findings to internal teams
  • Maintain detailed and accurate laboratory records in compliance with data integrity and documentation standards
  • Limited travel may be required
Desired Qualifications
  • Prior experience with nonhuman primate studies is preferred
  • Experience designing experiments to address pharmacokinetics/pharmacodynamics, biodistribution, or toxicology relationships is a plus
  • Experience with lipid nanoparticles or chimeric antigen receptor delivery technologies and genetic medicine platforms is a plus

Stylus Medicine develops in vivo genetic medicines by combining engineered, therapeutic-grade recombinases with non-viral lipid nanoparticle (LNP) delivery. This platform enables sequence-specific genome integration to insert large genetic payloads directly inside a patient’s body, bypassing the complex steps of ex vivo cell modification. The initial focus is in oncology, delivering a recombinase and a CAR-encoding DNA payload to a patient’s T cells via LNP infusion, effectively turning the patient’s body into an in vivo CAR-T cell factory. The modular system can adapt CAR constructs to target different cancer antigens and holds potential for autoimmune and other genetic diseases beyond oncology. The company positions itself as an off-the-shelf, scalable genetic therapy approach that streamlines treatment workflows and broadens patient access by avoiding traditional ex vivo manufacturing.

Company Size

11-50

Company Stage

Series A

Total Funding

$85M

Headquarters

Cambridge, Massachusetts

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $85M in 2025 from RA Capital, Khosla, Lilly, and J&J.
  • Preclinical in vivo CAR-T data presented at ASGCT 2025.
  • Led by CEO Nuwaysir with 25+ years in cell therapy.

What critics are saying

  • Prime Medicine's PRIME Editing partners with BMS in January 2025.
  • Beam's base editing hits 40% efficiency in NHPs at ASGCT May 2025.
  • Arc licenses Hsu's IP exclusively to CRISPR Therapeutics February 2026.

What makes Stylus Medicine unique

  • Stylus combines engineered recombinases with LNP for in vivo genome integration.
  • Platform enables precise insertion of multi-kb payloads into T-cells directly.
  • Avoids ex vivo manufacturing complexities of traditional CAR-T therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Stylus Medicine who can refer or advise you

Benefits

Professional Development Budget

Company News

The Pharma Letter
May 14th, 2025
Stylus Medicine launches with $85M funding

Stylus Medicine, a biotech company based in Cambridge, USA, has emerged from stealth mode with $85 million in funding.

Yahoo Finance
May 14th, 2025
Stylus Medicine launches with $85m to advance in vivo gene editing

Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline.

Fierce Biotech
May 13th, 2025
Stylus Medicine raises $85M for gene editing.

Stylus Medicine has emerged from stealth with $85 million in funding to develop next-gen in vivo genetic medicines. The financing includes a prior $40 million series A and a recent $45 million series A extension, with investors like RA Capital, Khosla Ventures, Eli Lilly, and J&J Innovation. Led by CEO Emile Nuwaysir, Stylus aims to simplify gene editing with a platform featuring recombinase technology. Preclinical data will be presented at the American Society of Gene & Cell Therapy meeting.

Endpoints News
May 12th, 2025
Stylus Medicine raises $85M for tech

Patrick Hsu's startup, Stylus Medicine, has launched with an ambitious goal to develop new gene insertion technologies beyond CRISPR. The company has successfully raised $85 million to support its development efforts.

Endpoints News
May 12th, 2025
Exclusive: Patrick Hsu startup launches, looks beyond CRISPR for gene insertion technology

Stylus Medicine, an ambitious startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes...